FISCHMANN, Thierry, Alan HRUZA, Jose DUCA, Lata RAMANATHAN, Todd MAYHOOD, William WINDSOR, Hung LE, Timothy GUZI, Michael DWYER, Kamil PARUCH, Ronald DOLL, Emma LEES, David PARRY, Wolfgang SEGHEZZI and Vincent MADISON. Structure-guided discovery of cyclin-dependent kinase inhibitors. Biopolymers. 2008, vol. 2008, No 89, p. 372-379. ISSN 0006-3525.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Structure-guided discovery of cyclin-dependent kinase inhibitors
Name in Czech Structure-guided discovery of cyclin-dependent kinase inhibitors
Authors FISCHMANN, Thierry (840 United States of America), Alan HRUZA (840 United States of America), Jose DUCA (840 United States of America), Lata RAMANATHAN (840 United States of America), Todd MAYHOOD (840 United States of America), William WINDSOR (840 United States of America), Hung LE (840 United States of America), Timothy GUZI (840 United States of America), Michael DWYER (840 United States of America), Kamil PARUCH (203 Czech Republic, guarantor), Ronald DOLL (840 United States of America), Emma LEES (840 United States of America), David PARRY (840 United States of America), Wolfgang SEGHEZZI (840 United States of America) and Vincent MADISON (840 United States of America).
Edition Biopolymers, 2008, 0006-3525.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10401 Organic chemistry
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.823
RIV identification code RIV/00216224:14310/08:00035899
Organization unit Faculty of Science
UT WoS 000254569700008
Keywords (in Czech) CDK2; kináza; inhibitor
Keywords in English CDK2; kinase; inhibitor
Tags CDK2, inhibitor, Kinase
Changed by Changed by: doc. Mgr. Kamil Paruch, Ph.D., učo 108413. Changed: 25/6/2009 16:11.
Abstract
CDK2 inhibitors containing the related bicyclic heterocycles pyrazolopyrimidines and imidazopyrazines were discovered through high-throughput screening. Crystal structures of inhibitors with these bicyclic cores and two more related ones show that all but one have a common binding mode featuring two hydrogen bonds (H-bonds) to the backbone of the kinase hinge region. Even though ab initio computations indicated that the imidazopyrazine core would bind more tightly to the hinge, pyrazolopyrimidines gain an advantage in potency through participation of N4 in an H-bond network involving two catalytic residues and bridging water molecules. Further insight into inhibitor/CDK2 interactions was gained from analysis of additional crystal structures. Significant gains in potency were obtained by optimizing the fit of hydrophobic substituents to the gatekeeper region of the ATP binding site. The most potent inhibitors have good selectivity.
Abstract (in Czech)
viz anotace
PrintDisplayed: 27/6/2024 12:31